Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: A pooled safety analysis

1. Zhou, Q.
2. Wu, Y.-L.
3. Corral, J.
4. Nakagawa, K.
5. Garon, E.B.
6. Sbar, E.I.
7. Wang, T.
8. Sandin, R.
9. Noonan, K.
10. Gernhardt, D.
11. Mok, T.S.